ランキングに戻る

BeiGene, Ltd. (ONC)

割高
HealthcareBiotechnologySwitzerland

ファンダメンタル

71

株価

$367.39

時価総額

$40.72B

パート1 · 企業の価値

概要

ONC trades under BeOne Medicines, formerly known as BeiGene, a global biotechnology company that discovers, develops and sells cancer drugs. Its lead product, Brukinsa, treats certain blood cancers by blocking an enzyme (BTK) the cancer cells need to survive. Unlike a diversified pharmaceutical company, BeOne's revenue and value are concentrated in a small number of approved oncology drugs sold through its own commercial teams in the United States, Europe and China.

収益の仕組み

Almost all revenue comes from product sales of approved drugs, chiefly Brukinsa, plus smaller in-licensed products such as Amgen's oncology portfolio that BeOne distributes in China. Because it sells directly rather than relying on royalties from a partner, it captures the full margin on each sale but also carries the cost of its own sales forces across multiple continents, and revenue depends on doctors continuing to prescribe its drugs over rival treatments.

セグメント別売上高

BRUKINSA73%

The company's lead BTK-inhibitor drug for blood cancers such as chronic lymphocytic leukemia, sold globally and the main driver of growth.

TEVIMBRA13.8%

An immunotherapy antibody used against several solid tumor cancers, the company's second-largest product.

Amgen in-licensed products9.1%

Oncology drugs originally developed by Amgen that BeOne markets and sells in China under a licensing agreement.

競争優位性(moat)

特許・ライセンス · 狭い

Patents on Brukinsa's chemical structure and manufacturing, plus regulatory approvals in dozens of countries, keep generic competitors out for a fixed period, and clinical data showing advantages over the first BTK inhibitor to market support doctor preference. The protection is time-limited by patent expiry and contestable by newer drugs in the same class, so it does not amount to a durable structural barrier.

需要を左右する要因

ディフェンシブ

Cancer treatment is not discretionary spending and demand does not track the economic cycle; growth instead depends on winning regulatory approvals for new indications, expanding into new countries, and doctors switching patients from older drugs. The main swing factor is clinical and regulatory success, not the broader economy.

主なリスク

  • Revenue concentration in a single drug — Brukinsa accounts for roughly three-quarters of revenue; a safety issue, a more effective competing drug, or loss of patent protection would have an outsized effect on the whole company.
  • Dependence on regulatory approvals — Selling a drug in a new country or for a new use requires approval from that country's health regulator, a process that can be delayed, restricted or denied regardless of clinical trial results.
  • Pricing and reimbursement pressure — Government and private payers in every market where the company sells negotiate or set drug prices and reimbursement terms, and unfavorable changes can reduce revenue on approved products without any change to the drug itself.
  • Clinical trial and pipeline risk — Future growth depends on drugs still in clinical trials succeeding and reaching approval; most experimental cancer drugs fail somewhere in that process, and a failure removes an assumed source of future revenue.

強気材料

Buyers argue that Brukinsa's clinical data advantages over older BTK inhibitors are winning doctor preference and market share even as the drug class matures, that expansion into Europe and other markets outside the US and China still has room to run, and that the company reaching full-year profitability in 2025 for the first time shows the commercial model scaling.

弱気材料

Sellers fear that concentrating three-quarters of revenue in one drug leaves little room for error if a safety signal, a stronger competitor or a reimbursement setback emerges, that US growth has already begun decelerating from its earlier triple-digit pace, and that sustaining growth requires the pipeline to deliver new approvals on a schedule biotech development rarely respects.

2025会計年度のセグメントデータ情報源: BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results

Written by the editors, published on 2026年8月18日

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 2026年9月19日 with claude-haiku-4-5 — shared with all users

P/E: 24.6Score: 61Market cap: $255.21B

Its BTK inhibitor Calquence (acalabrutinib) fights BeOne's Brukinsa for the same chronic lymphocytic leukemia and mantle cell lymphoma prescriptions, above all in the United States and Europe.

P/E: 73.9Score: 71Market cap: $470.55B

Imbruvica (ibrutinib), the first BTK inhibitor on the market and the drug BeOne ran its head-to-head trials against, plus Venclexta, compete for the same blood-cancer patients.

P/E: 38.8Score: 74Market cap: $1.11T

Its non-covalent BTK inhibitor Jaypirca (pirtobrutinib) targets the same leukemia and lymphoma patients, including those who have already progressed on a covalent BTK inhibitor like Brukinsa.

P/E: 116.2Score: 63Market cap: $366.84B

Keytruda (pembrolizumab) is the dominant PD-1 antibody and competes with BeOne's Tevimbra (tislelizumab) in oesophageal, gastric and lung cancer.

P/E: 13.7Score: 72Market cap: $130.49B

Opdivo (nivolumab) covers largely the same PD-1 indications as Tevimbra, particularly oesophageal and gastro-oesophageal tumours.

Innovent Biologics, Inc. (信達生物製藥)1801.HK

In China, where BeOne generates a large share of its revenue, Innovent's PD-1 antibody Tyvyt and its oncology portfolio compete for the same hospital formularies and reimbursement listings.

貸借対照表と流動性

売上高

$6.13B

直近12か月(2026/6/30まで)

純利益

$656M

直近12か月(2026/6/30まで)

フリーキャッシュフロー

$942M

自己資本合計

$4.36B

負債合計

$3.83B

流動比率

3.40

利払い倍率

7.97

負債/EBITDA

2.06

一株当たり利益(EPS)

売上高と純利益

フリーキャッシュフロー

収益内訳

財務推移表

利益率の推移

負債の推移

負債の重さ

成長率グリッド

成長率 — 売上高

適正価値の推定

一般的なケース割高

適正価値

$237.94

現在株価

$367.39

安全マージン

-54.4%

適正価値レンジ

$154.66 - $321.22

使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。

推定方法

アナリストの目標株価:$432.80
ディスカウンテッド・キャッシュフロー(DCF):$8.61
利益倍率(P/E):$282.92
グレアムの成長公式:$91.01
収益力価値(EPV):$23.98
正当化されたP/B:$23.09
配当割引モデル(ゴードン):$3.00
P/FFO(運用から生まれる資金):$4.64
中間サイクル利益:算出に必要なデータが不足しています
売上高倍率:$109.83
アナリスト・コンセンサス:強い買い (11B / 1H / 0S)

バリュエーション指標

P/E レシオ

831.68

ROE

6.6%

P/B レシオ

104.54

P/FCF

406.64

粗利益率

88.9%

ROIC

10.3%

収益性レーダー

価値創造(経済的モート)

ROIC

10.3%

WACC

12.6%

ROIC − WACC

-2.2 pp

ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。

ファンダメンタル分析基準

合格(20)

  • EPS shows upward trend
  • Price CAGR 28.24%
  • ROIC 10.3%
  • Gross Margin 88.9%
  • Debt/Equity ratio
  • Operating Margin 15.1%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • ROE 13.3%
  • Revenue Growth 5Y 78.3%
  • Analyst Consensus 92% Buy
  • Earnings Surprise avg 16.6%
  • Earnings Quality (OCF/NI) 2.26
  • Net Margin Trend 10.7% vs -3.9%
  • Piotroski F-Score 7/9

不合格(5)

  • P/FCF 406.64
  • P/B Ratio 104.54
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Share Dilution 10.1%

データなし(2)

  • Dividend Payout NaN%
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-スコア

7/9

財務健全性が高い

score
criteria

利益の質

2.26

高品質:利益はキャッシュに裏付けられている

株式希薄化

10.1%

新株を発行しており、所有権を希薄化している

機関投資家の保有

ガバナンス

経営陣

氏名役職年齢
Mr. John V. OylerCo-Founder, Executive Chairman & CEO57
Mr. Wang Lai Ph.D.President and Global Head of Research & Development48
Dr. Xiaodong Wang Ph.D.Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder62
Mr. Aaron RosenbergChief Financial Officer48
Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary57
Mr. Titus B. BallVP & Chief Accounting Officer51
Mr. Marcello DamianiChief Technology Officer55
Ms. Liza HeapesHead of Investor Relations-
Ms. Eleanor Duff Ph.D.Senior VP & Head of Corporate Communications-
Mr. Graham HardimanGlobal Head of Human Resources-

パート2 · 株価と買い時

この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。

書類

  • 年次報告書(10-K)

    事業内容、財務実績、リスクをまとめた年次の概要。

    提出日: 2026-02-26

    書類を見る
  • 四半期報告書(10-Q)

    直近3か月間の業績に関する最新情報。

    提出日: 2026-08-05

    書類を見る
  • 臨時報告書(8-K)

    経営陣の交代や重要な発表など、大きな出来事に関するお知らせ。

    提出日: 2026-08-26

    書類を見る

via SEC EDGAR

業績推移

via SEC EDGAR

Latest News

Recent headlines for ONC, sourced from Markets Gazette.

No recent news for ONC.